Evaluation of patient activation and dosimetry after Boron Neutron Capture Therapy

Giovanni Garini, Chiara Magni, Ian Postuma, Setareh Fatemi, Ricardo Ramos, Barbara Marcaccio, Cristina Pezzi, Laura Bagnale, Sandro Sandri, Gianfranco De Matteis, Giuseppe Paolisso, Valerio Vercesi, Silva Bortolussi* · 2025

Read Evaluation of patient activation and dosimetry after Boron Neutron Capture Therapy by Giovanni Garini, Chiara Magni, Ian Postuma, Setareh Fatemi, Ricardo Ramos, Barbara Marcaccio, Cristina Pezzi, Laura Bagnale, Sandro Sandri, Gianfranco De Matteis, Giuseppe Paolisso, Valerio Vercesi, Silva Bortolussi* (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2501-13053.txt.

Introduction

A cancer therapy that fires neutrons at boron-loaded tumors leaves the patient briefly radioactive. Giovanni Garini and co-authors measure how much that matters, in a 2025 study tied to a new Italian treatment center. Boron neutron capture therapy works because boron-10, delivered by a selective drug, splits under neutron fire into two short-range particles that kill the tumor cell from inside.

The team modeled and assessed the activation of organs and tissues after treatment and proposed a criterion for judging when it counts. Under Italian rules, the activation level poses no significant radiological concern, even soon after irradiation. The patient's excretions are the fussier problem, needing building design and discharge procedures to match. The study feeds the radiation-protection case for the accelerator-based center now being built.

Catalog record

CREATORGiovanni Garini, Chiara Magni, Ian Postuma, Setareh Fatemi, Ricardo Ramos, Barbara Marcaccio, Cristina Pezzi, Laura Bagnale, Sandro Sandri, Gianfranco De Matteis, Giuseppe Paolisso, Valerio Vercesi, Silva Bortolussi*
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37 KB
VERSION1.0
LICENSEhttp://creativecommons.org/licenses/by/4.0/
RIGHTSCC BY
SOURCEarXiv

Source: https://arxiv.org/abs/2501-13053

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Evaluation of patient activation and dosimetry after Boron Neutron Capture Therapy Giovanni Garini, Chiara Magni, Ian Postuma, Setareh Fatemi, Ricardo Ramos, Barbara Marcaccio, Cristina Pezzi, Laura Bagnale, Sandro Sandri, Gianfranco De Matteis, Giuseppe Paolisso, Valerio Vercesi, Silva Bortolussi* Abstract Boron Neutron Capture Therapy (BNCT) is a form of radiotherapy based on the irradiation of the tumour with a low energy neutron beam, after the administration of a selective drug enriched in boron-10. The therapy exploits the high cross section of thermal neutron capture in boron, generating two low-range charged particles. The availability of accelerators able to generate high-intensity neutron beams via proton nuclear interaction is boosting the construction of new clinical centres. One of these is under development in Italy, using a 5 MeV, 30 mA proton radiofrequency accelerator coupled to a beryllium target, funded by the Complementary Plan to the Recovery and Resilience National Plan, under the project ANTHEM. The present study focuses on radiation protection aspects of patients undergoing BNCT, specifically on the activation of their organs and tissues. A criterion to establish the relevance of such activation after BNCT has been proposed. Based on the current Italian regulatory framework, the level of patient activation following BNCT treatment does not pose a significant radiological concern, even shortly after irradiation. Another aspect is the activation of patient’s excretions, which can impact on the design of the building and requires a process for the discharge. The described study contributes to the radiation protection study for the ANTHEM BNCT centre in Italy. Journal: Arxiv † † highlights: The adult-patient model from ICRP-145 has been used for a benchmark between MCNP and PHITS A criterion for patients discharge after BNCT based on Italian regulation in nuclear medicine is proposed Activation of patients after BNCT has been studied in different irradiation positions Excretes activation has been evaluated Activation studies are pivotal in the BNCT facility design and management 1 Introduction The project ANTHEM (AdvaNced Technologies for Human-centrEd Medicine) is funded by the National Plan for Complementary Investments (PNC) in the call for technologies and innovative trajectories in the health and care sectors. Its purpose is to fill the existing gap in the healthcare of fragile and chronic patients within specific territories, characterized by pathologies that lack effective therapies. The project is organized into four spokes with different aims; the Pilot 9 of the Spoke 4 concerns the construction of a new facility for Boron Neutron Capture Therapy (BNCT) research and clinical application in Caserta, at the University of Campania "Luigi Vanvitelli", Italy. BNCT is a form of radiotherapy consisting in the irradiation with low energy neutrons of a tumour previously loaded with a sufficient concentration of boron-10 nuclei. The cross section of thermal neutron capture in 10 B is orders of magnitude higher than that for interaction with other elements in biological tissues. The reaction 10 B(n, \alpha ) 7 Li produces two particles with high Linear Energy Transfer (LET) and short range in biological tissue, which cause lethal damage to the cell where the capture occurs. Thus, provided a suitable tumour-to-normal tissue boron concentration ratio is achieved, a differential radiation dose deposition is attained in the malignancy, with a substantial sparing of healthy tissues [ 1 ] . The technology to generate the neutron beam for the ANTHEM project is designed and built by National Institute for Nuclear Physics (INFN) and it is based on a proton accelerator, a Be target and a Beam Shaping Assembly (BSA). The accelerator, developed by the National Laboratory of Legnaro (LNL) is a Radio Frequency Quadrupole (RFQ) machine delivering a 5 Mev, 30 mA proton beam in continuous wave [ 2 ] . The proton beam hits a Be-Pd-Cu target, also designed at LNL. Finally, the BSA to tailor the energy spectrum and collimation for patients is being developed in Pavia using an innovative method to select the best configuration of materials and to evaluate the therapeutic potential of the beam [ 3 ] . The neutron beam will be characterized by a flux of the order of 10^{9}cm^{-2}s^{-1} , as required by the IAEA guidelines [ 1 ] , starting from a neutron intensity of 10^{14}s^{-1} produced in the target [ 4 ] . The Pilot 4.9 of ANTHEM also addresses the design and construction of the building comprising the spaces for the neutron production technology, one patients’ irradiation room, one experimental room, and areas for patients and medical/research staff as shown in the plan in Fig. 1 . Figure 1: Building plan of ANTHEM project facility for BNCT in Caserta, Italy. The building will include rooms dedicated to the staff and patient preparation (boron administration and positioning), two irradiation rooms, one for clinics and one for research purposes, and laboratories for radiobiology, biochemistry and molecular medicine. The irradiation of patients with an intense neutron beam generates induced activation in the biological tissues and in the excretions and may pose some constraints in the management of patients in the post-treatment phase, an aspect to be addressed in accordance with the legislation currently in force in Italy regarding radiation protection. Patients activation could be a safety issue for people who will come in contact with them after the treatment, such as medical staff and family members. For this reason, it is necessary to evaluate the patient induced radioactivity and to calculate the dose that a person will absorb by being in proximity of the patient. This work presents these calculations and proposes a criterion to evaluate the dose due to this activation to take decisions on the discharge of patients, as there is no specific mention of this aspect in the radiation protection legislation concerning BNCT or neutron irradiation. The obtained results contribute to the radiation protection studies connected to the approval of the BNCT centre, to the design of the facility and to the establishment of the procedures from the patients admission to their discharge after the irradiation. 2 Materials and methods The current legislation governing radiation protection in Italy is Legislative Decree 101/2020, whose Title XIII contains the provisions on medical exposure to ionizing radiation. In accordance with the principles of radiation protection, in the case of patients treated with radiopharmaceuticals it is necessary to protect the people who will come in contact with them after treatment. As the Decree states in Annex XXV, post-treatment hospitalization is mandatory only for patients administered with Iodine-131 ( {}^{131}I ) at activity levels greater than 600 MBq. It can reasonably be assumed that, below this threshold, contact with a treated patient is safely acceptable from a radiation protection viewpoint. Therefore, since there are currently no specific provisions for patients undergoing neutron irradiation, we decided to compare the ambient dose due to the activation of a patient treated with BNCT to that of a patient treated with 600 MBq of {}^{131}I . As the quantity to calculate, we chose the ambient dose, a radiation protection parameter used to assess the dose in the air within a specific environment and the associated risk for individuals in that area. 2.1 ICRP phantom To simulate {}^{131}I treatment and BNCT irradiation, we selected the new adult mesh-type computational phantom from the ICRP publication nr. 145 [ 5 ] , made with a

Read the complete text